Autolus Therapeutics Wins 2026 Prix Galien UK Best Biotechnology Award
AUTL•Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, recognizing its leading T-cell therapy development. The award, selected by a 12-expert UK committee, underscores the company's advances in next-generation programmed T cell therapies for cancer and autoimmune disease.
1. Award Announcement
On June 12, 2026, Autolus Therapeutics received the Prix Galien UK Award for Best Biotechnology Product in recognition of its pioneering programmed T cell therapy program.
2. Prix Galien Selection Process
The award was chosen by a UK Awards Committee of 12 healthcare experts who evaluated candidates based on innovation, clinical impact and potential to transform medical practice.
3. Company Background and Impact
Founder Dr. Martin Pule highlighted the award as validation of Autolus's efforts translating University College London research into targeted T cell therapies, supporting ongoing development across hematological malignancies, solid tumors and autoimmune diseases.
